ScreenerHero

NGEN NervGen Pharma Corp.

NAS · US · Healthcare · Biotechnology · nervgen.com
1.740USD-0.57%Mkt Cap: 187.09M $P/E: —

NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease.…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap187.09M USD
Enterprise Value101.37M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-44.12M USD
Revenue/Share—
Last Price1.740 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees9
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.13
PEG—
EV/EBITDA-3.14
EV/Revenue—
P/S—
P/B15.11
EPS (TTM)-0.55
EPS (Forward)-0.34
52W Range
1.5803% of range6.300
52W High6.300 USD
52W Low1.580 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1268.86%
ROA-190.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-19.50M USD
CapEx (TTM)—
FCF Margin—
FCF Yield20.52%
Net Debt-86.79M USD
Net Debt/EBITDA2.69
Balance Sheet
Debt/Equity0.00
Current Ratio1.23
Quick Ratio1.19
Book Value/Sh0.12 USD
Cash/Share0.81 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.00 USD
Upside (mean)+474.7%
Target Range10.00 USD – 10.00 USD
# Analysts1
Ownership
Shares Out.107.52M
Float95.30M
Insiders15.63%
Institutions11.22%
Short Interest
Short Ratio9.1d
Short % Out.5.11%
Shares Short5.49M
Short (prev mo.)5.34M
Technical
SMA 501.937 (-10.1%)
SMA 2003.201 (-45.6%)
Beta0.82
S&P 52W Chg15.78%
Avg Vol (30d)519.50K
Avg Vol (10d)494.45K
Technical Indicators
RSI (14)36.4
MACD-0.0627
MACD Signal-0.0231
MACD Hist.-0.0395
BB Upper2.295 USD
BB Middle1.979 USD
BB Lower1.663 USD
BB Width31.96%
ATR (14)0.1171 USD
Vol Ratio (20d)0.47x